Format

Send to

Choose Destination
Drug Discov Today. 2003 Jan 15;8(2):86-96.

Nonleadlikeness and leadlikeness in biochemical screening.

Author information

1
Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. grishton@amgen.com

Abstract

Biochemical assays have largely supplanted functional biological assays as drug screening tools in the early stages of drug discovery. The de-selection of compounds that are 'nonleadlike' binders (and bonders) and the proactive selection of those compounds that are 'leadlike' in their binding to the target are vital components of the screening effort. The physiochemical properties of leadlikeness and the surprising differences between those properties and the now classical definitions of druglikeness are becoming apparent.

Comment in

PMID:
12565011
DOI:
10.1016/s1359644602025722
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center